Denali Therapeutics

dart board miss failure
Biotech

Denali’s ALS drug comes up short in trial extension

Denali’s amyotrophic lateral sclerosis drug has racked up another clinical miss this year, leaving the company to mull the asset’s future.
James Waldron Mar 6, 2025 8:20am
Sled dogs racing toward finish

Denali rare disease drug clears safety study, reduces biomarkers

Feb 6, 2025 12:05pm
space launch rocketship

Tenvie takes off with $200M, assets and exec from Denali

Jan 8, 2025 8:00am
Cartoon of businessmen standing around a broken target

Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests

Jan 7, 2025 5:52am
failure crash no fail rocket cancelled end

Sanofi flunks MS study, dealing another blow to Denali pact

Oct 11, 2024 5:56am
Pathological phosphorylation yellow of Tau proteins red-orange by kinases violett leads to disintegration of microtubul

Researchers receive $6.9M NIA grant for tau-targeting drug

Aug 21, 2024 1:02pm